(HealthDay News) — For patients in the Apixaban for Reduction of Stroke and Other Thromboembolic Complications in Atrial Fibrillation (ARISTOTLE) trial, the 5 mg twice daily dose of apixaban is ...

CHICAGO -- For extended anticoagulation after venous thromboembolism (VTE) in patients with active cancer, a lower dose of apixaban (Eliquis) was just as effective as a higher dose -- and safer, the ...

In the randomized COBRRA trial, apixaban was associated with substantially less clinically relevant bleeding than rivaroxaban ...

Study finds apixaban’s safety preferable over other anticoagulant medication following assessment of respective bleeding ...

Very elderly people with nonvalvular atrial fibrillation (Afib) got the same stroke prevention benefits from edoxaban (Savaysa) and apixaban (Eliquis), though one drug was associated with more major ...

Please provide your email address to receive an email when new articles are posted on . Reduced dosing of direct oral anticoagulants for VTE conferred comparable efficacy as full dosing. Reduced ...

Extended low-intensity anticoagulation with apixaban was associated with a reduction in symptomatic superficial vein thrombosis ...

Please provide your email address to receive an email when new articles are posted on . Apixaban did not reduce recurrent stroke risk in patients with atrial cardiopathy without AF. The ARCADIA trial ...

Asundexian 50 mg daily was inferior to apixaban for stroke and systemic embolism prevention in high-risk patients with atrial fibrillation (AF), according to late-breaking research presented in a Hot ...

If you're taking Eliquis (apixaban) to prevent blood clots and stroke, you've likely experienced sticker shock at the ...